Emergent BioSolutions Inc.
EBS
$5.08
$0.265.39%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 66.29% | -29.75% | -23.63% | -21.34% | -44.68% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 66.29% | -29.75% | -23.63% | -21.34% | -44.68% |
| Cost of Revenue | 44.15% | -19.69% | -23.58% | -23.61% | -78.92% |
| Gross Profit | 86.65% | -38.38% | -23.71% | -19.55% | 212.06% |
| SG&A Expenses | 2.06% | -11.07% | -12.87% | -57.06% | -43.47% |
| Depreciation & Amortization | 6.17% | 1.23% | 0.00% | 0.00% | -0.61% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.19% | -15.06% | -18.04% | -32.11% | -66.24% |
| Operating Income | 5,433.33% | -79.17% | -58.04% | 6.46% | 100.75% |
| Income Before Tax | -889.88% | -85.54% | -83.70% | -59.55% | 93.77% |
| Income Tax Expenses | 389.58% | -73.28% | 5.41% | -76.81% | -136.09% |
| Earnings from Continuing Operations | -1,401.67% | -90.00% | -74.44% | -55.40% | 95.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,401.67% | -90.00% | -74.44% | -55.40% | 95.76% |
| EBIT | 5,433.33% | -79.17% | -58.04% | 6.46% | 100.75% |
| EBITDA | 271.49% | -55.75% | -100.91% | 2.41% | 118.40% |
| EPS Basic | -1,477.33% | -89.52% | -80.43% | -55.49% | 95.89% |
| Normalized Basic EPS | 444.48% | -71.24% | -42.31% | -28.58% | 91.00% |
| EPS Diluted | -1,477.33% | -93.76% | -79.75% | -55.83% | 95.89% |
| Normalized Diluted EPS | 444.48% | -72.18% | -42.31% | -29.59% | 91.00% |
| Average Basic Shares Outstanding | -4.80% | -4.60% | -3.32% | 0.19% | 3.04% |
| Average Diluted Shares Outstanding | -4.80% | -1.40% | -3.32% | 1.62% | 3.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |